The Director of the Gene Therapy for Rare Diseases Program at CIMA Universidad de Navarra, co-founder and former CSO of Vivet Therapeutic.
She is a globally recognised for her expertise in fundamental AAV biology as well as the development and translation of AAV-based gene therapeutics. She has a strong record of leadership holding executive positions in major gene and cell therapy societies. Her pioneering work in advanced therapies for inherited metabolic disorders in the liver promises to transform the future of medicine for patients battling rare diseases.